Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Gains from Sales and Divestitures: 2016-2025

  • BIO-TECHNE's Gains from Sales and Divestitures rose 3.88% to $134,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $134,000, marking a year-over-year increase of 3.88%. This contributed to the annual value of $134,000 for FY2025, which is 3.88% up from last year.
  • As of Q2 2025, BIO-TECHNE's Gains from Sales and Divestitures stood at $134,000, which was up 3.88% from $129,000 recorded in Q2 2024.
  • Over the past 5 years, BIO-TECHNE's Gains from Sales and Divestitures peaked at $206,000 during Q2 2021, and registered a low of $123,000 during Q2 2023.
  • Over the past 3 years, BIO-TECHNE's median Gains from Sales and Divestitures value was $129,000 (recorded in 2024), while the average stood at $128,667.
  • As far as peak fluctuations go, BIO-TECHNE's Gains from Sales and Divestitures spiked by 303.92% in 2021, and later declined by 29.61% in 2022.
  • Over the past 5 years, BIO-TECHNE's Gains from Sales and Divestitures (Quarterly) stood at $206,000 in 2021, then decreased by 29.61% to $145,000 in 2022, then dropped by 15.17% to $123,000 in 2023, then climbed by 4.88% to $129,000 in 2024, then grew by 3.88% to $134,000 in 2025.
  • Its Gains from Sales and Divestitures was $134,000 in Q2 2025, compared to $129,000 in Q2 2024 and $123,000 in Q2 2023.